Managing squamous cell carcinoma of external auditory canal - A single institution experience [0.03%]
外耳道鳞状细胞癌的诊疗经验报告
Malu Rafi,John M Mathew,Lekha M Nair et al.
Malu Rafi et al.
External Auditory Canal (EAC) Squamous cell cancers are rare head and neck malignancies accounting for 0.2% of cancers of this region which has limited literature to guide management.We report a retrospective study patients with SCC of EAC ...
Efficacy and safety of first-line pemetrexed plus carboplatin followed by pemetrexed maintenance in newly diagnosed and metastatic elderly non-squamous Non-Small Cell Lung Cancer (NSCLC): Real World Data (RWD) of a Galician and Mediterranean lung cancer group [0.03%]
培美曲塞联合卡铂一线治疗后以培美曲塞维持治疗新诊断的非鳞状非小细胞肺癌(NSCLC)患者的疗效及安全性：加利西亚和地中海肺癌症登记数据库真实世界数据研究
Arias Ron David,Álvarez Fernández Javier,García Benito Carme et al.
Arias Ron David et al.
Background: The role of Pemetrexed combined with platinum chemotherapy in newly diagnosed and metastatic non-squamous NSCLC is clearly defined since the results of Paramount trial. Currently, platinum chemotherapy plus im...
The effect of postoperative chemotherapy on blood glucose and prognosis in patients with advanced ovarian cancer [0.03%]
术后化疗对晚期卵巢癌患者血糖及预后的影响
Ting Du,Xueli Zha,Yawen Zhang et al.
Ting Du et al.
Objective: Recent studies have shown that chemotherapy can cause abnormal glucose metabolism in cancer patients; however, little is known about the association of blood glucose (BG) with chemotherapy in ovarian cancer. In...
Management of immune-related adverse events under PD-1/PD-L1 inhibitors: Insights from a Moroccan real-world experience [0.03%]
Moroccan真实世界经验下的PD-1/PD-L1抑制剂相关免疫不良事件的处理措施及启示
Inès Cherradi,Mohamed Ichou,Mohammed Squalli Houssaini et al.
Inès Cherradi et al.
Background: PD-1 and PD-L1 inhibitors, including pembrolizumab and atezolizumab, have improved survival outcomes in several malignancies. However, their use is frequently associated with immune-related adverse events (irA...
Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia [0.03%]
埃克替尼一线治疗EGFR突变型晚期肺腺癌患者的真实世界无进展生存：一项印尼多中心研究
Noni Novisari Soeroso,Elisna Syahruddin,Chaliza Soliha et al.
Noni Novisari Soeroso et al.
Introduction: Afatinib, a second-generation EGFR tyrosine kinase inhibitor (TKI), has demonstrated clinical benefit in EGFR-mutant non-small cell lung cancer (NSCLC) through clinical trials. However, real-world data, part...
Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer [0.03%]
贝伐珠单抗类似药CT-P16与原研贝伐珠单抗治疗转移性或复发性非小细胞肺癌的随机、双盲III期临床试验的长期疗效和安全性结果
Zoran Andric,Fedor Moiseenko,Tamta Makharadze et al.
Zoran Andric et al.
Purpose: Data from the CT-P16 3.1 study demonstrated equivalent efficacy between CT-P16, a bevacizumab biosimilar, and European-approved reference bevacizumab (EU-bevacizumab) for the primary endpoint of objective respons...
Harnessing PUMA's lethal potential: BCL-2 family dynamics and novel strategies to combat cancer recurrence [0.03%]
发挥PUMA的潜在作用：BCL-2家族动力学和对抗癌症复发的新策略
Moustafa A Mansour,Mohamed Abdel-Fattah El-Salamoni,Hamdi Nabawi Mostafa
Moustafa A Mansour
Cancer cells often survive treatment by blocking the natural process of cell death, allowing them to return and grow again. The BCL-2 protein family plays a central role in this process, controlling whether a cell lives or dies. Among its m...
Advances in the management of lung & gastro-intestinal cancers: clinical studies review from ASCO 2022/2023 annual meetings [0.03%]
肺癌和消化系统癌症管理进展：ASCO 2022/2023年会临床研究回顾
Hafsa Elmarrachi,Meriem Andrif,Nabil Ismaili
Hafsa Elmarrachi
Advancements in cancer research play a pivotal role in enhancing prevention, diagnosis, and treatment strategies. The American Society of Clinical Oncology (ASCO) convenes major annual meetings, gathering experts worldwide to discuss the la...
A protocol for pre-treatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions - a retrospective cohort review [0.03%]
一项在使用西妥昔单抗前进行α半乳糖抗体检测的方案可降低过敏反应风险——回顾性队列研究
Nicholas Della Marta,Alexander Yuile,Claire Mok et al.
Nicholas Della Marta et al.
Purpose: Cetuximab improves survival in KRAS wildtype metastatic colorectal cancer. However, high rates of hypersensitivity reactions (HSRs) limit its use, with HSR rates up to 10-20 %. A major driver of cetuximab HSR is ...
Epidemiological description of genetic alterations and prognosis in Mexican patients with melanoma: a retrospective cohort [0.03%]
墨西哥黑色素瘤患者基因改变的流行病学特征和预后：一项回顾性队列研究
Katia F Ávila-Fernández,Héctor Martínez-Said,Ivan R González-Espinoza et al.
Katia F Ávila-Fernández et al.
Background: Melanoma is currently the most aggressive skin cancer. It is currently categorized based on mutations that have been studied for their prognostic relevance. ...